WASHINGTON, DC / ACCESS Newswire / November 16, 2025 / As Congress moves decisively to end the era of intoxicating hemp products and synthetic cannabinoids, a new chapter is opening for federally legal cannabis based medicines. With regulatory clarity emerging from the FDA, DEA, and bipartisan state authorities, MMJ International Holdings, Inc. now stands as the U.S. company fully positioned within the federal pharmaceutical pathway for cannabis drug development.
For a decade, MMJ pursued the rigorous FDA and DEA route-while the rest of the market chased loopholes, synthetics, and state-level workarounds. Today, with the hemp market collapsing under federal action, MMJ's no short cut strategy has become the blueprint for the industry's future.
I. Federal Hemp Shutdown Reshapes the Cannabinoid Landscape
In the wake of a sweeping federal appropriations bill, Congress is redefining hemp to include total THC, banning synthetic and semi-synthetic cannabinoids such as Delta-8, THC-O, HHC, THCP, and imposing a 4 mg total THC limit per container.
Original link
Copyright
©420 Intel